{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:17:49Z","timestamp":1786119469266,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,3]]},"DOI":"10.1097\/cad.0b013e3283350e26","type":"journal-article","created":{"date-parts":[[2010,2,2]],"date-time":"2010-02-02T01:44:05Z","timestamp":1265075045000},"page":"326-332","source":"Crossref","is-referenced-by-count":44,"title":["Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials"],"prefix":"10.1097","volume":"21","author":[{"given":"Tao","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomei","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanyi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daoyuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210227","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"Global cancer statistics, 2002.","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"R2-13-20210227","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S1479-666X(05)80043-5","article-title":"The continuing challenge of hepatic cancer in Asia","volume":"3","author":"Lai","year":"2005","journal-title":"Surgeon"},{"key":"R3-13-20210227","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJM199903113401001","article-title":"Rising incidence of hepatocellular carcinoma in the United States","volume":"340","author":"El-Serag","year":"1999","journal-title":"N Engl J Med"},{"key":"R4-13-20210227","first-page":"303","article-title":"The history of liver surgery","volume":"42","author":"Lau","year":"1997","journal-title":"J R Coll Surg Edinb"},{"key":"R5-13-20210227","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R6-13-20210227","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/01.SLA.0000048443.71734.BF","article-title":"Percutaneous local ablative therapy for hepatocellular carcinoma: a review and look into the future","volume":"237","author":"Lau","year":"2003","journal-title":"Ann Surg"},{"key":"R7-13-20210227","first-page":"105","article-title":"Combination therapy with radiofrequency ablation and transcatheter chemoembolization for the treatment of hepatocellular carcinoma: short-term recurrences and survival","volume":"11","author":"Yamakado","year":"2004","journal-title":"Oncol Rep"},{"key":"R8-13-20210227","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/S0140-6736(03)14964-1","article-title":"Hepatocellular carcinoma","volume":"362","author":"Llovet","year":"2003","journal-title":"Lancet"},{"key":"R9-13-20210227","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"R10-13-20210227","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1007\/s00280-006-0393-4","article-title":"Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models","volume":"59","author":"Chang","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"R11-13-20210227","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1055\/s-2006-960171","article-title":"Genomics and signaling pathways in hepatocellular carcinoma","volume":"27","author":"Villanueva","year":"2007","journal-title":"Semin Liver Dis"},{"key":"R12-13-20210227","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res"},{"key":"R13-13-20210227","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/0197-2456(94)00031-W","article-title":"Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists","volume":"16","author":"Moher","year":"1995","journal-title":"Control Clin Trials"},{"key":"R14-13-20210227","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat Med"},{"key":"R15-13-20210227","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"R16-13-20210227","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.2307\/2533446","article-title":"Operating characteristics of a rank correlation test for publication bias","volume":"50","author":"Begg","year":"1994","journal-title":"Biometrics"},{"key":"R17-13-20210227","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"R18-13-20210227","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Stat Med"},{"key":"R19-13-20210227","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"R20-13-20210227","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia\u2013Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"R22-13-20210227","doi-asserted-by":"crossref","first-page":"15624","DOI":"10.1200\/jco.2008.26.15_suppl.15624","article-title":"Sorafenib plus long-acting octreotide in advanced hepatocellular carcinoma. Preliminary results of a multicenter ongoing study","volume":"26","author":"Del Prete","year":"2008","journal-title":"J Clin Oncol"},{"key":"R23-13-20210227","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/1471-2407-8-349","article-title":"Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation-HeiLivCa [ISRCTN24081794]","volume":"8","author":"Hoffmann","year":"2008","journal-title":"BMC Cancer"},{"issue":"Suppl","key":"R24-13-20210227","doi-asserted-by":"crossref","first-page":"S6388","DOI":"10.1158\/1078-0432.CCR-040028","article-title":"Kinase inhibition with BAY 43-9006 in renal cell carcinoma","volume":"10","author":"Ahmad","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R25-13-20210227","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"R27-13-20210227","first-page":"109","article-title":"Systematic reviews in health care","author":"Clarke","year":"2001"}],"container-title":["Anti-Cancer Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CAD.0b013e3283350e26","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:18:51Z","timestamp":1786040331000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001813-201003000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/cad.0b013e3283350e26","relation":{},"ISSN":["0959-4973"],"issn-type":[{"value":"0959-4973","type":"print"}],"subject":[],"published":{"date-parts":[[2010,3]]}}}